Table 1-2.
Diagnosis and Treatment | ALL Patients (n = 15) |
---|---|
Diagnosis | |
ALL (HR) | 11 (73.3%) |
R/R ALL | 4 (26.7%) |
Chemical cycles | |
Consolidation | 8 (53.3%) |
Reinduction | 3 (20.0%) |
ALL-REZ BFM 2002 protocols | 4 (26.7%) |
ALL (HR), high risk of acute lymphoblastic luekemia; R/R ALL, relapsed and refractory acute lymphoblastic luekemia; ALL-REZ, Acute Lymphoblastic Leukemia-Relapse Study; BFM, Berlin-Frankfurt-Münster.